EDP Sciences logo
Submit your paper
Search
Menu
Home All issues Volume 28 / No 4 (2022) J Oral Med Oral Surg, 28 4 (2022) 42 Full HTML
Open Access

This article has an erratum: [https://doi.org/10.1051/mbcb/2023008]

Issue
J Oral Med Oral Surg
Volume 28, Number 4, 2022
Article Number 42
Number of page(s) 7
DOI https://doi.org/10.1051/mbcb/2022025
Published online 25 November 2022

© The authors, 2022

Licence Creative CommonsThis is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction

The human body has an enormous, remarkable, and determinant ability for self-healing. The disease is usually caused by abusing our bodies or depriving them of fundamental needs that keep us healthy for long periods of time. Despite the body's astonishing healing capacities, sometimes it needs a little help. The most fundamental aspect of wound healing is clot formation, and platelets are the principal cells responsible for clot formation [1].

The four critical phases of wound healing include the hemostasis, inflammatory, reparative, and remodelling phases. Blood clot (hemostasis phase) serves as a scaffold that allows cell movement and proliferation. If any deviation occurs at this stage, the healing cascade is altered and leads to unwanted complications [2]. Platelet concentrates (PC) provide these platelets and act as a scaffold, thus playing a significant role in the first and crucial stage of wound healing. The growth factors released from the alpha (α)-granules of platelets in these concentrates have additional benefits in other stages of wound healing [3].

Platelet concentrates are blood-derived products obtained after the centrifugation of a patient's own blood containing activated platelets enmeshed within a fibrin matrix scaffold. Since this process enhances the soft and hard tissues healing, PCs are being successfully used in numerous medical and dental fields over the last few decades [4,5].

The use of autologous PC in the different fields of dentistry started in the early 1970s. Apart from acting as a reservoir for growth factors, they have advantages such as patients' acceptance, cost-effectiveness, and no ethical issues as they are autologous in origin. However, these concentrates cannot be prepared in patients with thrombocytopenia, platelet dysfunction, or patients on systemic anticoagulants [6].

Periodontal healing is an orchestra of cells and signalling molecules, i.e., growth factors at an appropriate time in a suitable environment. There is substantial evidence regarding the application of growth factors in wound healing and the use of PC in Periodontology. However, with increasing research in this field, variations in the study characteristics, and results, there are speculations regarding their application in Periodontology. Hence, this article aims to comprehensively review the available in vitro studies and systematic reviews to understand the role of PC in Periodontology. (Review Question: What is the Role of Platelet concentrates in Periodontics).

Biological journey of platelet concentrates − from PRP to I-PRF

PRP was the first PC prepared with anti-coagulants using a two-spin centrifugation procedure [7]. Numerous fields of medicine, including dentistry, have used this invention to produce a six to eight times increase in growth factors at the site of application. Despite the extensive application of PRP in various fields, controversy existed regarding anti-coagulants, which negatively affect wound healing by inhibiting the formation of a clot, which is vital for the physiologic wound healing process [8]. Later, Platelet rich fibrin matrix (PRFM) was formulated, which demonstrated enhanced endothelial cell proliferation and angiogenesis in chronic wounds.

Choukroun et al., in the early 2000s, pioneered Platelet-rich fibrin, a unique formulation that employed collection and centrifugation of blood without anti-coagulants [9]. Two significant improvements reported were that the anti-coagulants did not inhibit the wound healing cascade and natural clot formation. Besides, PRF contains host immune cells (namely leukocytes), promoting local wound healing and fighting infection. PRF is a 3-dimensionally stable fibrin scaffold formed following 12 minutes of centrifugation [10]. Later, it was hypothesized that reduced centrifugation speeds and times would increase the leukocyte number and the growth factor release from PRF. When blood is centrifuged at low g-forces (700 g for 12 min (L-PRF) vs. 60 g for 3 min (i-PRF)), without anti-coagulants, a plasma-rich top liquid layer is formed, composed of fibrinogen and thrombin that have not yet converted to fibrin [11]. As a result, following centrifugation, i-PRF remains liquid for around 10–15 min before fibrin formation. Similar to PRP, i-PRF is now being used to provide angiogenic and regenerative growth factors. Unlike PRP, liquid PRF turns to fibrin quickly after being injected locally [8].

The PCs can be broadly classified into (Tab. I)

  • (1)

    Second generation − Includes L-PRF.

  • (2)

    Third generation − Includes A-PRF, i-PRF.

  • (3)

    Fourth generation − Currently under research (Focusing on tissue engineering triad).

Table I

Classification and preparation forms of various PCs.

Preparation of platelet concentrates

Numerous techniques are described in the literature for the preparation of platelet concentrates. Despite the heterogeneity in its preparation, one common finding is the use of anticoagulants in PRP preparation and centrifugation of whole blood without anticoagulants for PRF preparation. Heterogeneity for PRP still exists. However, the PRF preparation protocol is standardized with the introduction of the Choukroun PRF Duo Quattro System. PRF preparation needs a PRF box to compress the centrifuged PRF to form sheets or membranes. The methods and protocols are listed in Table II.

Table II

Methods and protocols for PC preparations.

Growth factors in platelet concentrate

The growth factors in platelet concentrates include platelet derived growth factor (PDGF), transforming growth factor (TGF), vascular endothelial growth factor (VEGF) and epidermal growth factor (EGF). The initial release of growth factors was better with PRP while prolonged release was observed with different PRF concentrates. PDGF was shown to be the most abundant growth factor produced from platelet concentrates (most with PRP), followed by PDGF-BB, TGF β1, VEGF, and PDGF-AB. Future studies should study the timing and concentration of the growth factor release to the timeline of the wound healing to achieve desired clinical results. The in vitro studies are listed in Table III.

Table III

Growth factors and platelet concentrates.

Discussion

Application of platelet concentrates in periodontology

Alveolar Ridge Preservation Procedures (ARP)

A systematic review involving five studies, evaluated the role of PCs in alveolar ridge preservation alone or in combination with bone grafts compared to controls. Of the 5 studies included, two studies had high risk of bias. The results have found that L- PRF minimized alveolar ridge resorption (vertical and horizontal dimensions) in ARP with or without bone grafts. PRP, on the other hand, might have no effects. Evidence shows that PC reduces postoperative pain, edema, trismus, and inflammation, enhancing patients' quality of life and comfort immediately after the ARP. The evidence on the effect on the proportion of new vital bone, however, is still inconclusive. Besides, scarce evidence shows that platelet concentrates positively affect new bone formation and bone density [17].

Another systematic review which included seven controlled trials (320 extractions in 190 patients) found similar results (improved soft tissue healing and reduced postoperative symptoms) but underlined the heterogeneity in the existing research in standardizing variables like type and location of the socket, computed tomography (CT) assessment of baseline alveolar bone levels, reason for extraction, and minimally traumatic extraction techniques. Furthermore, the evidence for the use of PC in the maintenance of the alveolar ridge is limited, necessitating research with adequate control groups [18].

Treatment of furcation involvement

The role of PC, in grade II or III furcation defects, as an adjunct to open flap debridement (OFD), bone grafts with OFD alone was compared in a systematic review and meta-analysis of randomized controlled studies with at least six months follow-up. A total of 10 studies were included, with only 1 study with high risk of bias. The results suggested improved outcomes in terms of clinical attachment level (CAL), vertical and horizontal furcation depths when PC were used as an adjunct to OFD. As an adjunct to bone grafts, improvements were seen only in horizontal CAL. Both PRF and PRP yielded favourable results. However, the data about the use of PC in combination with bone grafts and guided tissue regeneration (GTR) is scanty [19].

Gingival recession

The effect of autologous platelet concentrations as an adjunct to coronally advanced flap in the treatment of Millers Class I or II recessions was assessed in systematic review and meta-analysis of randomized trials. The study included 8 RCT involving 328 sites in 170 patients. The results show better clinical outcomes in root coverage for PRF, while PRP did not affect much. PRF had favourable outcomes in terms of RC, RD, CAL and Gingival thickness. However, though platelet concentrates could achieve root coverage, their effect on keratinized tissue width is minimal. Besides, they did not have any significant effect in combination with connective tissue grafts. The study results should be interpreted with caution as the included studies exhibited high risk of bias [20].

Surgical treatment of periodontal diseases and periodontal regeneration

PC showed a positive effect on CAL gain, irrespective of the treatment approach used as an adjunct to OFD in treating infra-bony defects. Besides, PC (PRP) had significant short-term effects when used as an adjunct to guided tissue regeneration. However, long-term data suggests the superiority of the GTR membrane. Nevertheless, considering the high cost, technique sensitivity, and patient acceptance for GTR membranes, the dense fibrin network in PRF membranes can act as a barrier membrane. They do, however, resorb as soon as 21 days, which is one of the drawbacks [21].

A Cochrane systematic review analysing 38 randomized controlled trials revealed a superiority of PC as an adjunct to OFD in terms of Pocket depth (PD) reduction, CAL gain, and radiographic bone fills compared to OFD alone. When used as an adjunct to OFD and bone grafts, a significant benefit in PD, CAL, Radiographic bone fill was reported with platelet concentrates compared to OFD + bone grafts. Besides, PC did not have any significance as an adjunct to enamel matrix derivate (EMD) in the treatment of furcation. However, the authors reported low-quality evidence regarding the analysed data [22].

Sinus augmentation procedures

Numerous studies evaluated the efficacy of PC on maxillary sinus augmentation. In a systematic review of clinical studies utilizing PRF in maxillary sinus lift procedures, PRF performed better as a sole filling material for sinus augmentation when implants are placed simultaneously, and PRF appeared to hasten the maturation of a demineralized freeze-dried bone (DFDB) allograft [23]. However, it did not affect deproteinized bovine maturation. Also, in a similar systematic review of randomized controlled trials, no changes were observed in implant survival, percentage of residual bone graft, new bone formation, contact between newly formed bone and bone substitute, and soft-tissue area compared to the non-PRF group [24]. However, in another systematic review and meta-analysis of PC evaluating their effect on maxillary sinus augmentation, PC may decrease the time needed for bone grafts to mature and allow for early implant placement. Nevertheless, they do not enhance long-term bone growth. Therefore, routine PCs are not recommended as osteoinductive material combined with bone grafts in sinus augmentation procedures [25]. Besides, a recent systematic review concluded that the current data is insufficient in using PC as an adjunct to bone graft in sinus augmentation [26].

PCs in comparison to other biomaterials

A recent systematic review has evaluated the effect of bioactive materials for the treatment of periodontal intra bony defects [27]. The study involved RCTs with a total of 259 patients with a follow-up period of 6-12 months. The study compared the effects of DFDBA and DFDBA+ bioactive material. The study results revealed PRP and PRF (PRF>PRP) to be better materials in terms of pocket depth reduction. In terms of CAL gain, PRF had a significant difference compared to other materials. In terms of bone fill, PRP had a significant effect. The study results suggest the superiority of PRP and PRF compared to other materials for the treatment of intra bony defects. However, most of the studies included had a moderate risk of bias.

Other oral applications of PC

In regenerative endodontics, the peri-apical bone fill was assessed, and it was noticed that L-PRF had better bone fill than the controls, but evidence regarding other PC is sparse and inconclusive. Moreover, PC can be used to achieve complete bone closure and complete resolution of MRONJ [28]. Furthermore, PRP can accelerate tooth movement in the short term but has no long-term effects. However, research is still on going with PC in these fields [29].

Clinical applications of I-PRF and A-PRF

Less than a decade ago, these two new formulations were proposed (A-PRF, 2014, i-PRF, 2016), and currently their biological basis is being understood. The research regarding their clinical application is still in nascent stages, and only time will prove their application in various clinical scenarios. However, few clinical studies and case reports show their application in Gingival recession [30], treatment of deep periodontal pockets [31,32], periodontal regeneration, enhancing gingival phenotype [33], orthodontic tooth movement [34,35], and various oral regenerative procedures. However, the evidence is weak to conclude their application in areas as mentioned above.

Clinical significance

The outcome of the current review substantiates:

  • Platelet rich fibrin (Injectable > Advanced > Leucocyte) have better release of growth factors when compared with the other PC, in vivo.

  • PC can be used as a better adjunct to various procedures in periodontology and implantology, with Platelet-rich fibrin, in most instances, has better clinical outcomes than other PC. This can be attributed to their three-dimensional structure, which contributes to better wound stability.

  • In root coverage Procedures, CGF and PRF are superior PC; however, only CGFs help in increasing keratinized gingiva, unlike PRF.

  • PC have a significant role in soft tissue healing and patient-centered outcomes; however, their role in hard-tissue regeneration is still unclear.

  • Most of the systematic reviews performed had a high-moderate risk of bias and low-quality evidence due to variations in study designs.

  • Heterogeneity in study designs in terms of preparation of PC is a frequent observation among the studies reporting PC outcomes.

  • The newest concentrates, such as i-PRF and A-PRF, are still in the early phases of development, and only rigorous testing procedures will show their therapeutic utility.

Conclusion

Platelet concentrates are abundant reservoir of growth factors and their selection has to be based on the type of defect and desired outcomes. PCs are excellent biomaterials for soft tissue healing, while their role in hard tissue healing is still unclear. The clinical outcomes with PC are way inferior to the results exhibited in vivo. Besides, there is an abundance of heterogeneity in the literature regarding their clinical application. Hence, Future well-designed RCTs should aim to deliver and exploit the inherent capabilities of these concentrates according to the timeline of the healing cascade to attain the best clinical outcome.

Conflict of interest

The authors declare that they have no conflicts of interest in relation to this article.

Informed consent

The authors declare that informed consent not required.

Ethical statement

The authors declare that Ethical approval not required.

Funding

This research did not receive any specific funding.

Author contribution statement

Study Concepts and Design: Raghavendra Vamsi Anegundi, Santhosh B. Shenoy Data Curation: Raghavendra Vamsi Anegundi, Santhosh B. Shenoy, Syeda Faiza Kaukab, Avaneendra Talwar Data Analysis and Interpretation: Raghavendra Vamsi Anegundi, Santhosh B. Shenoy, Syeda Faiza Kaukab, Avaneendra Talwar Manuscript preparation: Raghavendra Vamsi Anegundi, Santhosh B. Shenoy, Syeda Faiza Kaukab Final Editing and Review: Raghavendra Vamsi Anegundi, Santhosh B. Shenoy, Syeda Faiza Kaukab, Avaneendra Talwar.

References

  1. Palta S, Saroa R, Palta A. Overview of the coagulation system. Indian J Anaesth 2014;58:515. [CrossRef] [PubMed] [Google Scholar]
  2. Landén NX, Li D, Ståhle M. Transition from inflammation to proliferation: a critical step during wound healing. Cell Mol Life Sci 2016;73:3861–85. [CrossRef] [PubMed] [Google Scholar]
  3. Blair P, Flaumenhaft R. Platelet α-granules: basic biology and clinical correlates. Blood Rev 2009;23:177–89. [CrossRef] [PubMed] [Google Scholar]
  4. Whitman DH, Berry RL, Green DM. Platelet gel: an autologous alternative to fibrin glue with applications in oral and maxillofacial surgery. J Oral Maxillofacial Surg 1997;55:1294–9. [CrossRef] [Google Scholar]
  5. Narendran N, Anegundi RV, Shenoy SB, Chandran T. Autologous platelet‐rich fibrin as an adjunct to non‐surgical periodontal therapy—a follow up clinical pilot study. Wound Repair Regener 2022;30:140–5. [CrossRef] [PubMed] [Google Scholar]
  6. Saluja H, Dehane V, Mahindra U. Platelet-Rich fibrin: a second generation platelet concentrate and a new friend of oral and maxillofacial surgeons. Ann Maxillofacial Surg 2011;1:53. [CrossRef] [PubMed] [Google Scholar]
  7. Dhurat R, Sukesh M. Principles and methods of preparation of platelet-rich plasma: a review and author's perspective. J Cutaneous Aesthetic Surg 2014;7:189. [CrossRef] [PubMed] [Google Scholar]
  8. Miron RJ, Zhang Y. Autologous liquid platelet rich fibrin: a novel drug delivery system. Acta Biomater 2018;75:35–51. [CrossRef] [PubMed] [Google Scholar]
  9. Choukroun J, Adda F, Schoeffler C, Vervelle A. Une opportunité en paro-implantologie: le PRF. Implantodontie 2001;42:e62. [Google Scholar]
  10. Fujioka‐Kobayashi M, Miron RJ, Hernandez M, Kandalam U, Zhang Y, Choukroun J. Optimized platelet‐rich fibrin with the low‐speed concept: growth factor release, biocompatibility, and cellular response. J Periodontol 2017;88:112–21. [CrossRef] [PubMed] [Google Scholar]
  11. Miron RJ, Choukroun J. Platelet rich fibrin in regenerative dentistry: biological background and clinical indications, John Wiley & Sons; 2017. [CrossRef] [Google Scholar]
  12. Ghanaati S, Booms P, Orlowska A, Kubesch A, Lorenz J, Rutkowski J, et al. Advanced platelet-rich fibrin: a new concept for cell-based tissue engineering by means of inflammatory cells. J Oral Implant 2014;40:679–89. [CrossRef] [PubMed] [Google Scholar]
  13. Miron RJ, Fujioka-Kobayashi M, Hernandez M, Kandalam U, Zhang Y, Ghanaati S, et al. Injectable platelet rich fibrin (i-PRF): opportunities in regenerative dentistry? Clin Oral Invest 2017;21:2619–27. [CrossRef] [PubMed] [Google Scholar]
  14. Kobayashi E, Flückiger L, Fujioka-Kobayashi M, Sawada K, Sculean A, Schaller B, et al. Comparative release of growth factors from PRP, PRF, and advanced-PRF. Clin Oral Invest 2016;20:2353–60. [CrossRef] [PubMed] [Google Scholar]
  15. Arora S, Kotwal U, Dogra M, Doda V. Growth factor variation in two types of autologous platelet biomaterials: PRP Versus PRF. Indian J Hematol Blood Transfusion 2017;33:288–92. [CrossRef] [PubMed] [Google Scholar]
  16. Chatterjee A, Debnath K. Comparative evaluation of growth factors from platelet concentrates: an in vitro study. J Indian Soc Periodontol 2019;23:322. [CrossRef] [PubMed] [Google Scholar]
  17. Niu W, Wang P, Ge S, Ji P. Effects of platelet concentrates used in alveolar ridge preservation: a systematic review. Impl Dent 2018;27:498–506. [CrossRef] [PubMed] [Google Scholar]
  18. Annunziata M, Guida L, Nastri L, Piccirillo A, Sommese L, Napoli C. The role of autologous platelet concentrates in alveolar socket preservation: a systematic review. Transfus Med Hemother 2018;45:195–203. [CrossRef] [PubMed] [Google Scholar]
  19. Panda S, Karanxha L, Goker F, Satpathy A, Taschieri S, Francetti L, et al. Autologous platelet concentrates in treatment of furcation defects—a systematic review and meta-analysis. Int J Mol Sci 2019;20:1347. [CrossRef] [PubMed] [Google Scholar]
  20. Li R, Liu Y, Xu T, Zhao H, Hou J, Wu Y, et al. The additional effect of autologous platelet concentrates to coronally advanced flap in the treatment of gingival recessions: a systematic review and meta-analysis. BioMed Res Int 2019;2019. [Google Scholar]
  21. Del Fabbro M, Bortolin M, Taschieri S, Weinstein R. Is platelet concentrate advantageous for the surgical treatment of periodontal diseases? A systematic review and meta‐analysis. J Periodontol 2011;82:1100–11. [CrossRef] [PubMed] [Google Scholar]
  22. Del Fabbro M, Karanxha L, Panda S, Bucchi C, Doraiswamy JN, Sankari M, et al. Autologous platelet concentrates for treating periodontal infrabony defects. Cochrane Database System Rev 2018;11:CD011423. [Google Scholar]
  23. Ali S, Bakry SA, Abd-Elhakam H. Platelet-rich fibrin in maxillary sinus augmentation: a systematic review. J Oral Implantol 2015;41:746–53. [CrossRef] [PubMed] [Google Scholar]
  24. Liu R, Yan M, Chen S, Huang W, Wu D, Chen J. Effectiveness of platelet-rich fibrin as an adjunctive material to bone graft in maxillary sinus augmentation: a meta-analysis of randomized controlled trails. BioMed Res Int 2019;2019. [Google Scholar]
  25. Meng Y, Huang X, Wu M, Yang X, Liu Y. The effect of autologous platelet concentrates on maxillary sinus augmentation: a meta-analysis of randomized controlled trials and systematic review. BioMed Res Int 2020;2020. [Google Scholar]
  26. Ortega-Mejia H, Estrugo-Devesa A, Saka-Herrán C, Ayuso-Montero R, López-López J, Velasco-Ortega E. Platelet-rich plasma in maxillary sinus augmentation: systematic review. Materials 2020;13:622. [CrossRef] [PubMed] [Google Scholar]
  27. Zhou S, Sun C, Huang S, Wu X, Zhao Y, Pan C, et al. Efficacy of adjunctive bioactive materials in the treatment of periodontal intrabony defects: a systematic review and meta-analysis. BioMed Res Int 2018;2018. [Google Scholar]
  28. Al-Hamed FS, Mahri M, Al-Waeli H, Torres J, Badran Z, Tamimi F. Regenerative effect of platelet concentrates in oral and craniofacial regeneration. Front Cardiovasc Med 2019;6:126. [CrossRef] [PubMed] [Google Scholar]
  29. Liu L, Kuang Q, Zhou J, Long H. Is platelet-rich plasma able to accelerate orthodontic tooth movement? Evidence-Based Dent 2021;22:36–7. [CrossRef] [PubMed] [Google Scholar]
  30. Izol BS, Üner DD. A new approach for root surface biomodification using injectable platelet-rich fibrin (I-PRF). Medical Science Monitor 2019;25:4744. [CrossRef] [PubMed] [Google Scholar]
  31. Albonni H, El Abdelah AAAD, Al Hamwi MOMS, Al Hamoui WB, Sawaf H. Clinical effectiveness of a topical subgingival application of injectable platelet-rich fibrin as adjunctive therapy to scaling and root planing: a double-blind, split-mouth, randomized, prospective, comparative controlled trial. Quintessence Int (Berlin, Germany: 1985) 2021 [Google Scholar]
  32. Vučković M, Nikolić N, Milašin J, Đorđević V, Milinković I, Asotić J, et al. The effect of injectable platelet-rich fibrin use in the initial treatment of chronic periodontitis. Srpski arhiv za celokupno lekarstvo 2020;148:280–5. [CrossRef] [Google Scholar]
  33. Ozsagir ZB, Saglam E, Sen Yilmaz B, Choukroun J, Tunali M. Injectable platelet‐rich fibrin and microneedling for gingival augmentation in thin periodontal phenotype: a randomized controlled clinical trial. J Clin Periodontol 2020;47:489–99. [CrossRef] [PubMed] [Google Scholar]
  34. Zeitounlouian TS, Zeno KG, Brad BA, Haddad RA. Effect of injectable platelet-rich fibrin (i-PRF) in accelerating orthodontic tooth movement. J Orofac Orthoped/Fortschritte der Kieferorthopädie 2021:1–9. [Google Scholar]
  35. Erdur EA, Karakaslı K, Oncu E, Ozturk B, Hakkı S. Effect of injectable platelet-rich fibrin (i-PRF) on the rate of tooth movement: a randomized clinical trial. Angle Orthodontist 2021;91:285–92. [CrossRef] [PubMed] [Google Scholar]

All Tables

Table I

Classification and preparation forms of various PCs.

In the text
Table II

Methods and protocols for PC preparations.

In the text
Table III

Growth factors and platelet concentrates.

In the text

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.